Drug Price May Not Be Magic Bullet for Patient Access in LMICs

There has been a recent push from private, public, and legal fronts for drugmakers to reveal the prices they charge for medications worldwide to help improve access to patients, especially in lower- and middle-income countries (LMIC). However, Christine Truelove argues in a recent Value & Outcomes Spotlight article that this approach may be counterintuitive.

According to , “Revealing actual prices that the pharma industry gives to payers in low- and middle-income countries (LMICs) would simply encourage the exportation and resale of those products to higher-income countries. Additionally, establishing price transparency as a global concept would just make a price convergence where LMICs are forced to pay a higher price than they would have under the current tendered agreement system.”

To read more, click here.

(Source: Value & Outcomes Spotlight, December 2022)